MLchartDataset catalogue

Exicorilant

Term · Oncology and biomedicine · MLC-T-ONC-013484

An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.

Table 1. Record
IdentifierMLC-T-ONC-013484
FieldOncology and biomedicine
Synonymsglucocorticoid receptor antagonist CORT125281; selective GR antagonist CORT125134; WHO 10854
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013484",
  "term": "Exicorilant",
  "field": "Oncology and biomedicine",
  "definition": "An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.",
  "synonyms": [
    "glucocorticoid receptor antagonist CORT125281",
    "selective GR antagonist CORT125134",
    "WHO 10854"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/exicorilant/"
}

Record 7,025 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.